Biosensors   

Is Biosensors a good buy?

think they will issue a US$ cheque to u.

DrEaMzZz      ( Date: 30-Jul-2013 23:18) Posted: Tmr XD, will the share price down by US$ 0.02 and how they convert US$ 0.02 to Sing dollar? New123      ( Date: 30-Jul-2013 22:57) Posted: collect dividend US0.02 1st. think it may goes back to $1.20 level..

 

gut feeling the price will up.... hopefully.... < img src=" http://www.biosearch.co.il/wp-content/uploads/2011/04/D-SPECT-Machine.jpg" alt=" spectrum" />

 

Tmr XD, will the share price down by US$ 0.02 and how they convert US$ 0.02 to Sing dollar?

New123      ( Date: 30-Jul-2013 22:57) Posted: collect dividend US0.02 1st. think it may goes back to $1.20 level..

 

collect dividend US0.02 1st. think it may goes back to $1.20 level.. 

 

NOMURA Securities says ... BIOSENSORS INTERNATIONAL | BUY | TP: S$1.80 We caught up with the management of Biosensors at its AGM yesterday and highlight the following takeaways: Management indicated that it will continue to be on the lookout for M& A opportunities to grow the group into a global medical devices platform group The acquisition of Spectrum Dynamics (SD) provides an opportunity for the group to broaden its offering in the cardiovascular space The SD imaging machine could potentially help doctors ascertain the appropriate treatment for patients with heart disease A trial is being conducted in Japan to confirm the applications that the SD imaging machine can offer As at 31 March 2013, Biosensors has a net cash position of US$337m Management appeared confident of its guidance of 15% growth in product revenue, underpinned by its core DES business as it gains market share in spite of a stagnating global DES market Biosensors will launch 4 new products this year including Biomatrix Neoflex, BioFreedom and two balloon catheters under license from Eurocor Through joint marketing efforts with Terumo, Biosensors hopes to stabilize its market position in Japan and improve sales Plans are underway to seek regulatory approval for BioFreedom in Japan To a question from a shareholder if the group will address the US market, management indicated that while the US market is attractive, the group will need to find the best way to address the market eventually Enrolment for both its LEADERS FREE and GLOBAL LEADERS trials are progressing well (LEADERS Free is a prospective, randomized double blind trial between a DES and a bare metal stent involving patients with high risk of bleeding The primary end point is safety with one month course of DAPT.) The data from LEADERS FREE will be used to support the marketing of BioFreedom We reiterate our Buy Rating for Biosensors with price target of S$1.80 The shares look attractively valued at 12x FY2014 EPS with an earnings CAGR of 11% over the next 3 years

yiming2000      ( Date: 25-Jul-2013 22:49) Posted: I attended the AGM today. There was a lot of anger over loss of shareholder value by one guy who shouted that if othing is done, soon Biosensors will become a penny stock. Anyway, I dare not look at my paper losses. You may like to know that another shareholder pointed out that the Chairman does not have a substantial stock holding anymore. He must have been that mysterious BB who was dumping it. I noticed that 80% of Biosensors stocks are held by top 7 shareholders - all China investment companies. Any smart guys want to figure out what monkey business is going on here?

 

I attended the AGM today. There was a lot of anger over loss of shareholder value by one guy who shouted that if othing is done, soon Biosensors will become a penny stock. Anyway, I dare not look at my paper losses. You may like to know that another shareholder pointed out that the Chairman does not have a substantial stock holding anymore. He must have been that mysterious BB who was dumping it.

I noticed that 80% of Biosensors stocks are held by top 7 shareholders - all China investment companies. Any smart guys want to figure out what monkey business is going on here? 

 

 

 

 

 

Anyone wants to attend the AGM to vote against the payment of directors fees can have my proxies.  The kelong directors don deserve it.

New123      ( Date: 11-Jul-2013 14:33) Posted: gd! CD will drive the shares prices higher..i am in. halleluyah      ( Date: 08-Jul-2013 17:31) Posted: Finally gives dividend USD 0.02.

 

gd! CD will drive the shares prices higher..i am in.

halleluyah      ( Date: 08-Jul-2013 17:31) Posted: Finally gives dividend USD 0.02.

 

Nomura reiterates $1.80 target for BiosensorsAnalysts:  Jit Soon Lim, CFA, &   Wen Jie ChanBiosensor's Axxess stent in a blood vessel.Illustration from companyWe lower our earnings for FY14F and FY15F by 6% to reflect the higher  costs the group will likely incur as it expands its product base and  supports its newly acquired medical imaging business.  The higher costs,  in our view, will be mitigated by stronger revenue growth from new product  launches. We forecast EPS growth of 8% this year before accelerating to  15% CAGR over the following two years.  We reiterate our Buy rating with  a price target of SGD1.80.Shares oversold following “disappointing” 4Q results.  Biosensors has pulled back by 9% post the 4Q results at the end of May.  Valuations are attractive, in our view, at 12x FY14 EPS, underpinned by  our sum-of-the-parts valuation of SGD1.80 per share and net cash of  USD337mn (SGD0.25 per share).  In addition, the group will pay a  dividend of USD0.02/share by early August 2013

 

Finally gives dividend USD 0.02.

 

Maybank-KE maintains Hold with $ Not time for re-entry, Maintain Hold with $1.17 TP and caution investors that its not time to reenter yet. While share price is at 24% off its 52-wk peak of SGD1.42, flag further risks in licensing revenue from Terumo which could cap share price recovery. More aggressive marketing efforts for Nobori stent in Japan could result in higher distribution cost. House cut FY3/14F-16F net profits by 6-7% as it raise distribution cost assumptions which were too conservative. Think that share price appreciation in the near-term may still be capped despite the price decline due to the mentioned risks. Norges Bank and Atlantis Capital have recently trimmed their positions with the former ceasing to be a substantial shareholder

 

Biosensors International - More Risks to Licensing Revenue
Author: kimeng | Publish date: Thu, 4 Jul 09:22

Not time for re-entry, Maintain Hold. While share price is at 24% off its 52-wk peak of SGD1.42, we flag further risks in licensing revenue from Terumo which could cap share price recovery. More aggressive marketing efforts for Nobori stent in Japan could result in higher distribution cost. We cut FY3/14F-16F net profits by 6-7% as we raise our distribution cost assumptions which were too conservative. Not time for re-entry, maintain Hold, SOTP-based TP trimmed to SGD1.17.

Terumo developing in-house DES. We note in Terumo’s “The New Mid-Term Plan (FY2013 – FY2016)” dated May 2013 that a new Drug Eluting Stent (DES) was introduced in its product pipelines. Based on our checks, a clinical trial has been initiated by Terumo for a new DES named “Discovery123/TCD-10023”, which is expected to be completed in 2014. We believe that this could be the same DES mentioned in Terumo’s plans. We suspect that this is intended to eventually replace the Nobori DES once the licensing agreement with Biosensors expires in 2016. We believe that Biosensors had foreseen this and this could be the part of the reason why it is building up its own sales team in Japan. Licensing income from Terumo accounts for ~15% of FY3/14F revenue but ~45% of net profit. Our TP has been substantially lower than consensus as we valued licensing based on DCF only until 2016.

Hard to quantify long term potential. Biosensors has a sound business strategy to transform into a multi-product platform and we recognise the long-term potential that could arise if it is successful. The company has been buying back its shares during the price decline, affirming their confidence. Biosensors still has over USD500m in cash which we believe is mostly earmarked for acquisitions. However, given the difficulties in quantifying the long-term potential and risks from M&As without more clarity, we have been holding back our optimism.

Maintain Hold, await positive catalysts. We think that share price appreciation in the near-term may still be capped despite the price decline due to the mentioned risks. Norges Bank and Atlantis Capital have recently trimmed their positions with the former ceasing to be a substantial shareholder. Maintain Hold, with TP reduced to SGD1.17. We await value accretive M&As as potential catalysts for upgrade.

Source: Maybank Research - 4 Jul 2013

Labels: Biosensors

 

Think it will cont to move up..

New123      ( Date: 26-Jun-2013 20:37) Posted: U turn liao. Will go higher tmr

 

KIV

 

Another married deal of 1m at 1.07

 

Company share buy back or BB start moving in?

 

Married deal 1m shares at 1.07

 

Technically,Biosensors (B20)   is upgraded to a buy with the 1.36 target price in six months.  is uhttp://sgx.stoxline.com/quote.php?s=b20

 

U turn liao. Will go higher tmr

 

Yiming2000 for u..Notice it remains quite strong at 44cts,on April 2013,SIC has approved the whitewash waiver for the land aquisition in the Iskandar Region,one of the conditions pertaining to this land aquisition.The 2nd half of this year,probably soon 2 free warrants for every 1 existing shares held,the warrants can be exercised into mother shares at $0.18..should head higher once shareholders approved but on Mon June 24 is the normal AGM

 

 

I went in to buy again 43-44cts after taking quick profit...Biosensor latest shareinvestercom mag..break $1.08 

downside expected next critical support $0.75 but put a stop should it moved > $1.08..wow recommending to short Biosensor??? maybe true limited upside but once economic bad news this sicko get shotdown again 

yiming2000      ( Date: 19-Jun-2013 10:59) Posted: Friend starlene, I am in the USA and won't be attending Rowsley AGM. I would love to meet you there if I could. Please report on what you see on June 24.   You are the guide to good fortune.